South Korean pharmaceutical companies Bujeong Pharmaceutical and Samjin Pharmaceutical both launched third-generation epilepsy treatments this week, intensifying competition in the domestic market. Bujeong Pharmaceutical released “Bujeong Brivil Tablet” (active ingredient: brivaracetam) on Tuesday, February 24, 2026, following its approval by the Ministry of Food and Drug Safety in September 2025, according to a company statement. Samjin Pharmaceutical launched “Briseatam Tablet” (brivaracetam) on February 22, 2026, building on its position as the leading generic epilepsy drug provider in Korea with its existing product, “Epilatam” (levetiracetam).
Bujeong Brivil is indicated as adjunctive therapy for patients with partial-onset seizures. The drug’s active ingredient, brivaracetam, selectively binds to synaptic vesicle protein 2A (SV2A), regulating neurotransmitter release and suppressing seizures, Bujeong Pharmaceutical stated. The company is offering the drug in 10mg, 25mg, 50mg, and 100mg dosages, allowing for individualized treatment plans. A Bujeong Pharmaceutical representative stated the drug is expected to improve the quality of life for epilepsy patients, citing its rapid onset of action and favorable safety profile.
Samjin Pharmaceutical’s Briseatam is also a brivaracetam-based treatment, developed as an improved version of its existing levetiracetam drug, Epilatam. The company highlighted the structural improvements to the drug as a key differentiator.
Bujeong Pharmaceutical anticipates that the availability of Bujeong Brivil, alongside its existing “Orfil family” of epilepsy treatments (immediate-release tablets, syrup, and injectable solutions), will provide neurologists with expanded treatment options. The company plans to further strengthen its position in the central nervous system (CNS) therapeutic area and continue investing in the development of treatments for neurological disorders, according to a company statement.
The launches come as the market for epilepsy treatments evolves, with a focus on newer generation drugs offering improved efficacy and tolerability. Both companies emphasized the potential for personalized medicine through varied dosage options.
